Onco-Innovations Ltd. is a Canadian biotech company, which engages in cancer research and treatment, specializing in oncology. The company is headquartered in Calgary, Alberta. The company went IPO on 2024-11-27. The firm holds an exclusive worldwide license to patented technology that targets solid tumors. The firm is engaged in developing and commercializing treatments for various types of cancer. Its solution focuses on targeting cancer cells, effectively eliminating them and preventing their regrowth. Its licensed technology focuses on Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. Its SynoGraph platform merges genomic, proteomic, and multimodal datasets to uncover deep insights into disease mechanisms, potentially enabling more personalized and effective treatment strategies.
Follow-Up Questions
Who is the CEO of Onco-Innovations Ltd?
Mr. Thomas Oshaughnessy is the Chief Executive Officer of Onco-Innovations Ltd, joining the firm since 2024.
What is the price performance of ONNVF stock?
The current price of ONNVF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Onco-Innovations Ltd?
Onco-Innovations Ltd belongs to Biotechnology industry and the sector is Health Care
